
TEM · NASDAQ
Tempus AI, Inc.
$79.33 +1.56 (+2.01%)
Company overview
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a licensed library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials, which provides clinical trial matching services to pharmaceutical companies.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Exchange
- NASDAQ
- Market cap
- $14.1B
- Employees
- 2,400
- Headquarters
- Chicago, IL
- Website
- tempus.com
- CEO
- Eric Lefkofsky
- Listed
- June 14, 2024
- P/E
- -46.39
- Dividend yield
- 0.00%
Company financials
- Revenue
- $1.4B
- Gross profit
- $949M
- Operating income
- -$247M
- EBITDA
- -$200M
- Net income
- -$303M
- EPS
- -$1.71
- Total assets
- $2.1B
- Total debt
- $815M
- Gross margin
- 69.55%
- Net margin
- -22.20%
- Earnings yield
- -2.16%
No geographic segmentation.
Showing FY 2025
News